OAG
CRSP icon

Orbis Allan Gray’s CRISPR Therapeutics CRSP Stock Holding History

Orbis Allan Gray’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297M Sell
5,449,161
-656,850
-11% -$34.6M 1.02% 34
2026
Q1 		$290M Buy
6,106,011
+155,866
+3% +$8.22M 1.23% 32
2025
Q4 		$312M Buy
5,950,145
+968,060
+19% +$58M 1.31% 30
2025
Q3 		$323M Buy
4,982,085
+2,217,553
+80% +$127M 1.39% 28
2025
Q2 		$134M Buy
2,764,532
+1,201,600
+77% +$46.5M 0.65% 42
2025
Q1 		$53.2M Buy
1,562,932
+86,813
+6% +$3.68M 0.3% 53
2024
Q4 		$58.1M Buy
+1,476,119
New +$69.7M 0.31% 51

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Orbis Allan Gray's CRSP Position: Q2 2026 in Review

Orbis Allan Gray reduced its CRISPR Therapeutics (CRSP) stake by 11% in Q2 2026, selling an estimated $34.6M and leaving 5,449,161 shares worth $297M. The position accounts for 1.02% of the portfolio, ranked #34.

Orbis Allan Gray first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $323M in Q3 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Orbis Allan Gray held 5,449,161 shares of CRISPR Therapeutics worth $297M as of Q2 2026.
  • Orbis Allan Gray sold 656,850 CRISPR Therapeutics shares in Q2 2026, an estimated $34.6M.
  • CRISPR Therapeutics made up 1.02% of Orbis Allan Gray's portfolio in Q2 2026, its #34 holding.
  • Orbis Allan Gray first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Orbis Allan Gray's CRISPR Therapeutics position peaked at $323M in Q3 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Orbis Allan Gray's 13F filing for Q2 2026, filed 14 Aug 2026.